Johnston SS, et al. - Using de-identified electronic health records linked to insurance claims data, researchers examined the association of body mass index (BMI) and insulin use with type 2 diabetes-related healthcare expenditures (T2D-HE). The study included a prevalence-based sample of T2D-treated overweight or obese patients. Participants in the study were 13,026 patients. Strong associations were found between BMI, insulin use, and T2D-HE in this large population-based study of commercially insured and Medicare Advantage patients with T2D and overweight/obesity. According to this retrospective study, BMI and use of insulin are simple stratifiers for high-cost patient identification. OCIII users of insulin have incurred the highest annual healthcare expenses; these patients might be an ideal group for targeted interventions. Together, BMI and insulin use were jointly linked to one-year follow-up T2D-HE, which ranged from $5842 in overweight patients without insulin to $17,700 OCIII users monotonically.